Alkami Wins "Best New Community" for Digital Network Connecting Customers like Kennebec Savings Bank
PLANO, Texas, June 11, 2025 /PRNewswire/ -- Alkami Technology, Inc. (Nasdaq: ALKT) ("Alkami"), a leading cloud-based digital banking solutions provider for financial institutions in the U.S., today announced that it has been named the winner of the Best New Community award at the 2025 CMX Community Industry Awards, recently hosted at the CMX Summit 2025 in Redwood City, California.
Now in its sixth year, the CMX Community Industry Awards celebrate the achievements of community professionals and teams across the globe. The Best New Community category honors an online community launched or relaunched after January 1, 2024, that has rapidly grown, engaged members, and demonstrated early success.
Launched in April 2024, Alkami went through a strategic transformation to introduce an open-access experience with role-based permissions, self-registration, streamlined navigation, real-time analytics, and a host of new engagement opportunities like forums and events. Building on the strong foundation of its legacy platform, Alkami transitioned to Gainsight's Customer Communities solution to create a single destination to connect, share best practices, and self-serve.
"A thriving customer community is essential to delivering long-term value," said Wayne McCulloch, chief customer officer at Alkami. "We invested in this initiative to give our customers a stronger voice and a place to collaborate, innovate, and grow together." Aaron White, senior community manager at Alkami continued, "We set out to create more than a forum; we built a true hub for connection, feedback, and shared success. Seeing customers embrace it so quickly and enthusiastically has been very rewarding."
Highlights from the Alkami Community for 2024 include:
A 96.6% customer adoption rate, with nearly every customer represented.
An 85% customer satisfaction score, with the majority of members rating the Community as highly valuable.
Membership growth from 275 to over 3,600 users.
35+ Community events, with a 67% attendance rate and 96% customer satisfaction.
A revitalized user group program and a popular "Tip Tuesday" content series.
Amy Driscoll, digital experience manager at Kennebec Savings Bank, shared, "I'm grateful for this Community. It's an incredible resource and always has helpful people. I can't wait to see what comes next."
With this award, Alkami continues to demonstrate its commitment to innovation, not only in digital banking technology, but also in customer engagement and community-building.
To learn more about Alkami's Digital Banking Platform, visit here.
Alkami has been certified by J.D. Power in 2024 and 2025 for providing "An Outstanding Mobile Banking Platform Experience."1
About Alkami Alkami Technology, Inc. is a leading cloud-based digital banking solutions provider for financial institutions in the United States that enables clients to grow confidently, adapt quickly, and build thriving digital communities. Alkami helps clients transform through retail and business banking, onboarding and account opening, payment security, and data and marketing solutions. To learn more, visit www.alkami.com.
Media Relations ContactsVestedalkami@fullyvested.com
Marla Pietonmarla.pieton@alkami.com___________________________________1J.D. Power 2025 Mobile App Platform Certification ProgramSM recognition is based on successful completion of an audit and exceeding a customer experience benchmark through a survey of recent servicing interactions. For more information, visit www.jdpower.com/awards.View original content to download multimedia:https://www.prnewswire.com/news-releases/alkami-wins-best-new-community-for-digital-network-connecting-customers-like-kennebec-savings-bank-302478993.html
SOURCE Alkami Technology, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J., August 01, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
16 minutes ago
- Business Wire
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ('KORU Medical' or the 'Company'), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the 'Freedom System') currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit
Hamilton Spectator
16 minutes ago
- Hamilton Spectator
Wall Street falls the most since May after employers slash hiring and tariffs roll out
The U.S. stock market had its worst day since May on Friday after the government reported a sharp slowdown in hiring and President Donald Trump imposed sweeping tariffs on imports from a number of U.S. trading partners. The S&P 500 fell 1.6%, its biggest decline since May 21 and its fourth straight loss. The index is also posted a 2.4% loss for the week, marking a sharp shift from last week's record-setting streak of gains. The Dow Jones Industrial Average fell 1.2%, while the Nasdaq composite fell 2.2%. Worries on Wall Street about a weakening economy were heavily reinforced by the latest report on job growth in the U.S. Employers added just 73,000 jobs in July. That is sharply lower than economists expected. The Labor Department also reported that revisions shaved a stunning 258,000 jobs off May and June payrolls. Markets also reacted to the latest tariff news . President Donald Trump announced tariff rates on dozens of countries and pushed back the scheduled effective date to Aug. 7, adding more uncertainty to the global trade picture.
